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Abstract
Objective— Atherosclerosis is a vascular disease that involves lesion
formation at sites of disturbed flow under the influence of genetic and
environmental factors. Endothelial expression of adhesion molecules that
enable infiltration of immune cells is important for lesion development.
Platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31) is an adhesion
and signaling receptor expressed by many cells involved in atherosclerotic
lesion development. PECAM-1 transduces signals required for
proinflammatory adhesion molecule expression at atherosusceptible sites;
thus, it is predicted to be proatherosclerotic. PECAM-1 also inhibits
inflammatory responses, on which basis it is predicted to be atheroprotective.
Methods and Results— We evaluated herein the effect of PECAM-1
deficiency on development of atherosclerosis in LDL receptor–deficient mice.
We found that PECAM-1 has both proatherosclerotic and atheroprotective
effects, but that the former dominate in the inner curvature of the aortic arch
whereas the latter dominate in the aortic sinus, branching arteries, and
descending aorta. Endothelial cell expression of PECAM-1 was sufficient for its
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atheroprotective effects in the aortic sinus but not in the descending aorta,
where the atheroprotective effects of PECAM-1 also required its expression on
bone marrow–derived cells.
Conclusion— We conclude that PECAM-1 influences initiation and progression
of atherosclerosis both positively and negatively, and that it does so in a sitespecific manner.
Keywords: PECAM-1, CD31, atherosclerosis, LDL-receptor, inflammation

Atherosclerosis is a chronic inflammatory disease that involves
formation, at discrete regions within the vasculature, of lesions
characterized by the presence of inflammatory cells, lipid deposits, and
extracellular matrix deposition.1 Atherosclerotic lesions form
preferentially at sites of vessel branching or high vessel curvature,
which are exposed to low shear stresses or oscillatory or turbulent
flow; however, genetic and environmental factors that determine
circulating lipid levels, gender and immune status strongly influence
lesion development in atherosusceptible regions.2 Endothelial cells
respond to low shear stress in atherosusceptible regions with increased
expression of adhesion molecules that enable recruitment and
infiltration of immune cells that contribute to lesion development.3
Nevertheless, the roles of individual adhesion molecules in regulating
atherosclerotic lesion development are not completely understood.
PECAM-1 is expressed on the surfaces of many cells involved in
atherosclerotic lesion development, including monocytes, lymphocytes,
platelets, and endothelial cells.4 PECAM-1 expression is equally
distributed over the entire surface of the aorta, including advanced
lesions, and does not appear to be affected by hemodynamic forces or
lipid levels.5,6 PECAM-1 engages in homophilic7 and heterophilic8
interactions at sites of cell–cell contact. On the basis of its role as a
critical component of a mechanotransducing complex that is required
for expression of proinflammatory adhesion molecules at
atherosusceptible sites,9 PECAM-1 has been predicted to have
proatherosclerotic properties.3 However, PECAM-1 also functions to
inhibit both systemic and organ-specific inflammatory responses10–18
and the oxidative environment in the vasculature,19,20 on the basis of
which PECAM-1 might be predicted to be atheroprotective.
The purpose of this study was to determine whether the
proatherosclerotic or atheroprotective effects of PECAM-1 dominate in
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an in vivo situation. We therefore evaluated the effect of PECAM-1
deficiency on development of atherosclerosis in LDL receptor–deficient
mice. We found that PECAM-1 has both proatherosclerotic and
atheroprotective effects in LDLR-deficient mice, but that the former
dominate in the inner curvature of the aortic arch whereas the latter
dominate in the aortic sinus, branching arteries, and descending aorta.
On the basis of these findings, we conclude that PECAM-1 influences
initiation and progression of atherosclerosis both positively and
negatively, and that it does so in a site-specific manner.

Methods
Animals and Diet
Mice were maintained in a facility free of well defined pathogens
under the supervision of the Biological Resource Center at the Medical
College of Wisconsin (MCW). Animal protocols were approved by the
MCW Institutional Animal Care and Use Committee. Mice were housed
in groups of 4 per cage, maintained under alternating 12-hour light
and dark cycles, and had free access to food and water. PECAM-1–
deficient (pecam-1−/−) mice,21 backcrossed for more than 10
generations onto a C57BL/6J background, were crossbred with LDL
receptor–deficient (ldlr−/−) mice (Jackson Laboratory, Bar Harbor,
Maine). Subsequently, pecam-1+/−ldlr−/− offspring were bred to obtain
pecam-1+/+ldlr−/− and pecam-1−/−ldlr−/− mice. The resulting genetic
background was 98.6% C57BL/6 and 1.4% 129Sv. Six- to 8-week-old
male and female pecam-1+/+ldlr−/− and pecam-1−/− ldlr−/− were placed
on a high-fat diet (HFD; Western-Type Diet TD 88137; Harlan Teklad)
containing 42% of calories derived from fat. Age- and gender-matched
pecam-1+/+ldlr−/− relative to pecam-1−/− ldlr−/− mice gained similar
amounts of weight over 24 weeks on the HFD (Table).
Table. Plasma Lipid Analysis and Weight Gain of Mice After 24 Weeks on the
HFD
Variable

Pecam1+/+ldlr−/−
Male

Pecam1−/−ldlr−/−
Male

Pecam1+/+ldlr−/−
Female

Pecam1−/−ldlr−/−
Female

Results are expressed as mean±SE. No statistically significant differences were found
between the groups.
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Variable

Pecam1+/+ldlr−/−
Male

Pecam1−/−ldlr−/−
Male

Pecam1+/+ldlr−/−
Female

Pecam1−/−ldlr−/−
Female

Cholesterol,
mg/dL

1335±280
(n=6)

1605±167
(n=8)

1048±120
(n=9)

1291±152 (n=9)

Triglycerides,
mg/dL

302±97 (n=5)

354±62 (n=8)

120±25 (n=9)

184±19 (n=9)

HDL
Cholesterol,
mg/dL

335±36 (n=7)

374±29 (n=7)

340±25 (n=9)

367±16 (n=9)

Body Weight, g

37±2.8 (n=10)

44±3.8 (n=8)

33±1.6 (n=14)

34±1.7 (n=11)

Plasma Lipid Analyses
Plasma aliquots (100 μL) of blood collected by cardiac puncture
from anesthetized mice were stored at −80°C. Levels of total
cholesterol, HDL cholesterol, and triglycerides, which were determined
in individual aliquots by the clinical laboratory at Children’s Hospital of
Wisconsin using the Vitros 5.1 fractional shortening (FS) Chemistry
System (Ortho-Clinical Diagnostics), did not differ significantly
between age- and gender-matched pecam-1+/+ldlr−/− and pecam1−/−ldlr−/− mice after 24 weeks on the HFD (Table 1).

Preparation of Mouse Aortas and Quantification of
Atherosclerosis
The heart and aorta of each animal were perfused, dissected
out, and subjected to quantification of atherosclerosis as previously
described.22,23 Briefly, to quantitate atherosclerosis in the aortic sinus,
the heart was embedded in optimal cutting temperature (OCT)
medium and frozen, after which serial sections (10 μm) were taken
from the aortic sinus and valve region.22 Images were obtained of the
sections after staining with oil red O (neutral lipid; counterstaining
with hematoxylin), and lesion area was quantified using SPOT image
analysis software (Diagnostic Instruments). The percent lesion area in
each section was calculated as follows: lesion area/total area
surrounded by aortic wall × 100. The mean percent atherosclerotic
lesion area for each animal was determined by averaging 4 to 6
sections from each mouse, using 60 to 80 μm intervals between
sections. To quantify atherosclerosis in the aorta by the en face
method, the entire aortic tree was dissected free of fat and other
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tissue. The aorta was stained with oil red O and digitally scanned.
Lesion area was assessed using Adobe Photoshop software and
expressed as a percent of the total surface area encompassed by the
aortic arch, inner curvature of the arch, thoracic aorta, abdominal
aorta, or total aorta as indicated.

Immunohistochemistry
Serial cryostat sections of aortic sinus adjacent to oil red O–
stained sections were stained with Sirius Red to detect collagen or
antimouse CD68 (1:100, AbD Serotec) and a tyramide amplification
plus kit (Perkin Elmer) to identify macrophages. Sections stained with
anti-CD68 were counterstained with DAPI to visualize nuclei.
Quantification of macrophage and collagen content was determined by
computer-assisted image analysis and expressed as percentage of
lesion area.

Ex Vivo Micro-CT Imaging and Quantification of Plaque
Volume
Mouse aortic specimens were dissected free of fat and incubated
overnight with 2% osmium tetroxide (OT).24,25 Prepared aortic samples
were placed in a 1.5-mL plastic microcentrifuge tube and subjected to
computed tomography (CT) scanning using a custom Keck microfocal
X-ray imaging system at the Zablocki VA Medical Center (Milwaukee,
Wisc). Details of the microfocal x-ray CT system and CT reconstruction
methods were described previously.26 Briefly, the imaging system
comprises a 3-μm focal-spot cone-beam X-ray source, precise
specimen manipulation stage, and image intensifier coupled to a
charge-coupled device (CCD) camera. Planar images (360, in 1o
increments) of the aortic samples were acquired with source-tospecimen distance of 4.6 cm, source-to-detector distance of 71.5 cm,
source current of 222 μA, and source voltage of 36 kV. A Feldkamp
algorithm was used to produce isotropic (4973 pixels) 3-D
reconstructions with 12.8 μm/pixel resolution. Floating-point grayscale
voxel values were scaled to 8-bit [0(air)-255(punctate accumulations
of OT)] for normalization and reduction of memory and processing
requirements. Data were visualized and morphometrics (based on
regional lesion volume) performed using multidimensional imaging
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software Analyze 8.0.26,27 A single observer defined threshold-based
images of the vessel wall (threshold 52) and plaque (threshold 93).
Lesion volumes were quantified in defined areas of the aortic arch
(24.1±2.5 mm2) and proximal parts of the three major branching
arteries, including the innominate (13.1±0.5 mm2), left common
carotid (4.8±0.2 mm2), and left subclavian (3.6±0.2 mm2) arteries.

Creation of Radiation Chimeras
Bone marrow cells were collected from the femur and tibia of
pecam-1+/+ldlr−/− or pecam-1−/−ldlr−/− donor mice and the small
mononuclear cell-enriched fraction was injected into irradiated, 4- to
6-week-old pecam-1+/+ldlr−/− or pecam-1−/−ldlr−/− recipient mice as
previously described.13 Transplant recipients were fed a normal chow
diet for 4 weeks, after which they were maintained on the HFD for an
additional 24 weeks. Flow cytometry was performed on whole blood
obtained from recipients at 12 weeks after transplantation to ensure
that full engraftment had taken place, with both CD3-positive
leukocytes and platelets examined for PECAM-1 expression
(supplemental Figure I).

Statistical Analysis
Data are presented for each individual animal or as mean±SEM.
Differences between means were analyzed using 2-tailed unpaired
Student t test or 2-way ANOVA followed by Bonferroni posthoc testing
using GraphPad Prism 4 software (GraphPad Software Inc).

Results
PECAM-1 Deficiency Renders LDLR-Deficient Mice More
Susceptible to Development of Atherosclerotic Lesions
in the Aortic Sinus
To determine whether the mechanosensory or antiinflammatory
role of PECAM-1 dominates in atherosclerosis, we tested the effect of
PECAM-1 deficiency on development and progression of atherosclerosis
in LDL receptor–deficient mice.28 We first evaluated the time course
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over which atherosclerotic lesions develop in the aortic sinus (Figure
1A and 1B). Both pecam-1−/−ldlr−/− and pecam-1+/+ldlr−/− mice
developed similarly small atherosclerotic lesions in the aortic sinus
after 8 weeks on the HFD (fractional lesion areas [FLA] −4.6±0.7%
[n=7] and 3.7±0.5% [n=8], respectively). However, after 16 weeks
on the HFD, atherosclerotic lesions in the aortic sinuses of pecam1−/−ldlr−/− mice were significantly larger than were those in pecam1+/+ldlr−/− mice (FLA −36.4±2.0% [n=8] and 25.9±1.7% [n=8],
respectively) and this difference persisted through 24 weeks on the
HFD (FLA −41.8±1.2% [n=14] and 36.3±1.6% [n=20], respectively).
Differences in aortic sinus lesion areas between pecam-1−/−ldlr−/− and
pecam-1+/+ldlr−/− mice were statistically significant when both genders
were evaluated together and when each gender was evaluated
separately (data not shown). Because the composition of
atherosclerotic lesions, along with lesion size, is critically important in
atherogenesis, cell and matrix components of the lesions were also
characterized by analyzing macrophage and collagen content,
respectively. After 24 weeks on the HFD, macrophage content in
atherosclerotic lesions of the aortic sinus was significantly greater in
pecam-1−/−ldlr−/− mice than in pecam-1+/+ldlr−/− mice (Figure 1C and
1D), whereas collagen deposition was similar between the 2 groups of
mice (Figure 1E and 1F). These results indicate that PECAM-1 inhibits
development of, and macrophage accumulation in, atherosclerotic
lesions in the aortic sinus of LDLR-deficient mice.
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Figure 1. PECAM-1 suppresses atherosclerotic lesion development in the aortic
sinuses of LDLR-deficient mice. A, Each symbol represents the mean percent
atherosclerotic lesion area calculated from 4 to 6 oil red O–stained sections spanning
the aortic sinus of an individual pecam-1+/+ldlr−/− (filled squares) or pecam-1−/−ldlr−/−
(open circles) mouse maintained on a HFD for the indicated time. Horizontal lines
indicate mean percent lesion area for each group of animals. Asterisks denote
statistically significant differences between groups (**P<0.01, ***P<0.001). B,
Representative oil red O–stained aortic sinus sections from pecam-1+/+ldlr−/− (top) and
pecam-1−/−ldlr−/− (bottom) mice fed a HFD for 24 weeks. C, Quantitative analysis of
macrophage content in aortic sinus lesions of pecam-1+/+ldlr−/− (filled bars) or pecam1−/−ldlr−/− (open bars) mice fed a HFD for 24 weeks. Results are expressed as the
mean percent of atherosclerotic lesion area occupied by CD68+ macrophages ±SE.
Asterisks denote statistically significant differences between groups (**P<0.01). D,
Representative anti-CD68–stained aortic sinus sections from pecam-1+/+ldlr−/− (top)
and pecam-1−/−ldlr−/− (bottom) mice. E, Quantitative analysis of collagen deposition in
aortic sinus lesions of pecam-1+/+ldlr−/− (filled bars) or pecam-1−/−ldlr−/− Figure 1
(Continued). (open bars) mice fed a HFD for 24 weeks. Results are expressed as the
mean percent of atherosclerotic lesion area containing collagen, as identified by
staining with Sirius Red, ±SE. F, Representative Sirius Red–stained aortic sinus
sections from pecam-1+/+ldlr−/− (top) and pecam-1−/−ldlr−/− (bottom) mice.
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PECAM-1 Deficiency Renders LDLR-Deficient Mice More
Susceptible to Development of Atherosclerotic Lesions
in the Descending Aorta
We next assessed the effect of PECAM-1 deficiency on
development of atherosclerotic lesions in the aorta of LDLR-deficient
mice by en face staining with oil red O. We found that lesion area in
the aortic arch as a whole did not differ significantly between pecam1+/+ldlr−/− and pecam-1−/−ldlr−/− mice after 24 weeks on the HFD
(Figure 2). However, lesion areas in both the thoracic and abdominal
aorta, and thus the total aorta, were significantly greater in pecam1−/−ldlr−/− relative to pecam-1+/+ldlr−/− mice (Figure 2). These results
reveal that, as it does in the aortic sinus, PECAM-1 inhibits
development of atherosclerotic lesions in the descending aorta of
LDLR-deficient mice.

Figure 2. PECAM-1 suppresses atherosclerosis in the descending aorta. A, Each
symbol represents the percent of total area of the indicated section of aorta that
stained positively for oil red O in individual pecam-1+/+ldlr−/− (filled squares) or
pecam-1−/− ldlr−/− (open circles) mice maintained on a HFD for 24 weeks. Horizontal
lines indicate mean percent lesion area in the indicated aortic section, including the
aortic arch, thoracic aorta, abdominal aorta, and total aorta (aortic arch+thoracic
aorta+ abdominal aorta), for each group of animals. Asterisks denote statistically
significant differences between groups (***P<0.001). B, Representative oil red O–
stained aortas from pecam-1+/+ldlr−/− (top) and pecam-1−/−ldlr−/− (bottom) mice
maintained on a HFD for 24 weeks.
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PECAM-1 Affects Atherosclerotic Lesion Development in
the Aortic Arch in a Site-Specific Manner
We observed a distinct pattern of plaque development in aortic
arches of pecam-1+/+ldlr−/− relative to pecam-1−/− ldlr−/− mice by en
face staining with oil red O. The pecam-1+/+ldlr−/− mice had
significantly larger lesions along the inner curvature of the arch but
smaller lesions in branching arteries compared to the pecam-1−/−ldlr−/−
mice (Figure 3A and 3B). We therefore decided to evaluate the effect
of PECAM-1 deficiency on development of atherosclerotic lesions in the
aortic arch in more detail using another method. We used
microcomputed tomography (micro-CT), which is a powerful imaging
technique for visualization of small specimens.24 Micro-CT has been
recently used to visualize the artery wall and early atherosclerotic
lesions both with25 and without29 OT as a contrast agent. Micro-CT
images revealed striking differences in plaque localization in pecam1+/+ ldlr−/− relative to pecam-1−/−ldlr−/−mice. Specifically, in pecam1+/+ldlr−/− mice, lesions were less extensive in the aortic branches and
more extensive along the inner curvature of the aortic arch (Figure
3C). In contrast, pecam-1−/−ldlr−/− mice developed substantial
atherosclerosis in branching arteries but few lesions along the inner
curvature of the arch (Figure 3). By visualizing the specimen in 3
dimensions, it is apparent that plaque was extensively distributed
along the inner curvature of the arch and only minimally present along
the lateral wall of the innominate artery (IA) and left common carotid
artery (LCCA) of pecam-1+/+ldlr−/− mice (supplemental Figure II),
whereas plaque was broadly distributed along the lateral walls of all 3
branching arteries and restricted to small patches along the inner
curvature of the arch in pecam-1−/−ldlr−/− mice (supplemental Figure
III). We also used OT in micro-CT to quantify plaque volume over
defined areas of vessel wall within discrete regions of the aortic arch.
We found that pecam-1+/+ldlr−/− mice had significantly more plaque
volume than did pecam-1−/−ldlr−/− mice along the inner curvature of
the arch; however, this was offset by the presence of significantly
greater plaque volume in the branching arteries of pecam-1−/−ldlr−/−
relative to pecam-1+/+ldlr−/− mice, such that plaque burden in the total
aortic arch as a whole was similar in pecam-1+/+ldlr−/− and pecam1−/−ldlr−/− mice (Figure 3D). Overall, these results indicate that
PECAM-1 expression in LDLR-deficient mice is proatherosclerotic along
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the inner curvature of the aortic arch but atheroprotective in aortic
branches.

Figure 3. PECAM-1 influences the site of atherosclerotic lesion development in the
aortic arch. A, Each symbol represents the percent of inner curvature area of the
aortic arch that stained positively for oil red O in individual pecam-1+/+ldlr−/− (filled
squares) or pecam-1−/−ldlr−/− (open circles) mice maintained on a HFD for 24 weeks.
Horizontal lines indicate mean percent lesion area for each group of animals. Asterisks
denote statistically significant differences between groups (***P<0.001). B,
Representative oil red O–stained aortas from pecam-1+/+ldlr−/− (left) and pecam1−/−ldlr−/− (right) mice maintained on a HFD for 24 weeks. C, Representative falsecolor micro-CT images of osmium tetroxide-stained aortas from pecam-1+/+ldlr−/−
(left) and pecam-1−/−ldlr−/− (right) mice maintained on a HFD for 24 weeks. Lesions
along the inner curvature (IC) of the aortic arch are shown in green, lesions in the 3
major branches emanating from the aortic arch (innominate artery [IA], left common
carotid artery [LCCA], and left subclavian artery [LSCA]) are shown in magenta, and
lesions in the descending aorta are shown in blue. D, Quantitative analysis of
atherosclerotic plaque volume in the IC of the aortic arch, the proximal IA, LCCA, and
LSCA, the sum of branches (IA + LCCA + LSCA) or the total aorta (sum of branches +
IC of aortic arch) of pecam-1+/+ldlr−/− (filled bars; n=6) vs pecam-1−/−ldlr−/− (open
bars; n=5) mice maintained on a HFD for 24 weeks. Results are expressed as mean
plaque volume ±SE. Asterisks denote statistically significant differences between
groups (*P<0.05, ***P<0.001).
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Endothelial Cell PECAM-1 Expression Protects Against
Development of Atherosclerosis in the Aortic Sinuses of
LDLR-Deficient Mice
PECAM-1 is expressed on both endothelial cells and bone
marrow–derived leukocytes and platelets, and is capable of
transducing signals that affect the function of cells from both of these
compartments.30 It was therefore important to determine whether the
effects of PECAM-1 on atherosclerosis required its expression on
endothelial cells, bone marrow–derived cells, or both. We created bone
marrow chimeric ldlr−/− mice that selectively expressed PECAM-1 either
on endothelium or bone marrow–derived cells (supplemental Figure I),
and measured atherosclerotic lesion sizes after feeding these mice a
HFD for 24 weeks. Unfortunately, the bone marrow transplantation
experiments did not recapitulate decreased lesion formation in the
lesser curvature of the arch in pecam-1−/− mice. The lesion area along
the inner curvature of the arch of ldlr−/− mice was comparable in
pecam-1+/+ recipients of pecam-1+/+ marrow and pecam-1−/−
recipients of pecam-1−/− marrow (supplemental Figure IV); therefore,
we could not use bone marrow chimeric mice to determine whether
endothelial or bone marrow–derived leukocyte or platelet expression of
PECAM-1 enhances lesion development in this region. However, like
untransplanted pecam-1−/−ldlr−/− relative to pecam-1+/+ldlr−/− mice,
pecam-1−/− recipients of pecam-1−/− bone marrow developed larger
lesions in the aortic sinus (Figure 4A) and total aorta (Figure 4B)
relative to pecam-1+/+ recipients of pecam-1+/+ marrow. Thus, bone
marrow chimeric mice could be used to determine the effects of
endothelial versus hematopoietic cell expression of PECAM-1 on lesion
development in the aortic sinus and total aorta of ldlr−/− mice.
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Figure 4. The effect of endothelial cell vs blood cell PECAM-1 expression on
development of atherosclerosis in LDLR–deficient mice. A, Endothelial cell PECAM-1
protects against development of atherosclerosis in the aortic sinus. Each symbol
represents the mean percent atherosclerotic lesion area calculated from 4 to 6 oil red
O–stained sections spanning the aortic sinus of an individual pecam-1+/+ldlr−/− (filled
symbols) or pecam-1−/−ldlr−/− (open symbols) recipient mouse transplanted with
pecam-1+/+ldlr−/− (squares) or pecam-1−/− ldlr−/− (circles) donor bone marrow and
maintained on a HFD for 24 weeks. Horizontal lines indicate the mean percent aortic
sinus lesion area for each group of animals. Asterisks denote statistically significant
differences between groups (*P<0.05, **P<0.01). B, Endothelial cell and blood cell
PECAM-1 expression are required for PECAM-1–mediated protection against
development of atherosclerosis in the aorta. Each symbol represents the percent of
total area of the indicated section of aorta that stained positively for oil red O in an
individual pecam-1+/+ ldlr−/− (filled symbols) or pecam-1−/−ldlr−/− (open symbols)
recipient mouse transplanted with either pecam-1+/+ldlr−/− (squares) or pecam1−/−ldlr−/− (circles) donor bone marrow and maintained on a HFD for 24 weeks.
Horizontal lines indicate mean percent lesion area in the indicated aortic section,
including the thoracic aorta, abdominal aorta, and total aorta (aortic arch + thoracic
aorta + abdominal aorta), for each group of animals. Asterisks denote statistically
significant differences between groups (*P<0.05, **P<0.01).

In the aortic sinus, lesions that developed in pecam-1+/+
recipients of pecam-1−/− marrow were similar in size to those of
pecam-1+/+ recipients of pecam-1+/+ marrow, and significantly smaller
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than the lesions that developed in pecam-1−/− recipients of pecam-1−/−
marrow (Figure 4A). Also, lesions that developed in the aortic sinuses
of pecam-1−/− recipients of pecam-1+/+ marrow were similar in size to
those of pecam-1−/− recipients of pecam-1−/− marrow and significantly
larger than the lesions that developed in pecam-1+/+ recipients of
pecam-1+/+ marrow (Figure 4A). These results indicate that endothelial
cell expression of PECAM-1 inhibits development of atherosclerotic
lesions in the aortic sinuses of ldlr−/− mice.
Interestingly, mice that were missing PECAM-1 from either
endothelial cells, bone marrow–derived leukocytes or platelets, or both
exhibited a trend toward increased lesion sizes in the thoracic and
abdominal aorta relative to mice that expressed PECAM-1 on both
endothelial and bone marrow–derived cells; however, these differences
did not reach statistical significance until lesion areas in the total aorta
were compared (Figure 4B). These results indicate that expression of
PECAM-1 on both endothelial and bone marrow–derived leukocytes or
platelets is required for PECAM-1 to inhibit development of
atherosclerotic lesions in the aortas of ldlr−/− mice.

Discussion
The major finding of this study is that PECAM-1 expression
affects development of atherosclerosis differently at different lesionprone sites of the vasculature. Specifically, PECAM-1 is
proatherosclerotic in the inner curvature of the aortic arch, but
atheroprotective in the aortic sinus, branching arteries, and
descending aorta. The atheroprotective effect of PECAM-1 in the aortic
sinus requires PECAM-1 expression only on endothelial cells, whereas
PECAM-1 expression on both endothelial cells and bone marrow–
derived cells is required for its atheroprotective effects in the
descending aorta.
The proatherosclerotic effect of PECAM-1 in the inner curvature
of the arch is consistent with its role as part of a mechanostimulatory
complex on endothelial cells that activates NF-kB in response to low
shear stress and induces expression of adhesion molecules that enable
recruitment of inflammatory cells into the lesion.9 A
mechanostimulatory function for PECAM-1 is supported by the findings
in many,9,31–33 but not all,34 studies that PECAM-1 facilitates responses
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of cultured endothelial cells to osmotic and fluid shear stresses.
Previous studies have established that PECAM-1 is rapidly
phosphorylated on cytoplasmic tyrosine residues in cultured
endothelial cells exposed to fluid shear or osmotic stress31–36; however,
whether PECAM-1 tyrosine phosphorylation is required for its
mechanostimulatory function is not yet known.
The atheroprotective effect of PECAM-1 in the aortic sinus,
branching arteries, and descending aorta indicates that PECAM-1
normally inhibits development of atherosclerosis in these regions of
the vasculature. Our studies of bone marrow chimeric mice revealed
that the cells on which PECAM-1 must be expressed to inhibit lesion
development vary by vascular region. Specifically, in both the aortic
sinus and descending aorta, the atheroprotective effect of PECAM-1
required its expression on endothelial cells; in the aortic sinus, PECAM1 expression on endothelial cells alone was sufficient for its inhibitory
function. Two functions of the endothelium that impact lesion
development in atherosusceptible regions include maintenance of the
vascular permeability barrier and insurance of nitric oxide (NO)
bioavailability.2 PECAM-1 has been shown to support maintenance of
vascular integrity in at least 4 different models of inflammation,
including intradermal injection of histamine,11 autoimmune
encephalomyelitis,11 collagen-induced arthritis,12,15 and
lipopolysaccharide (LPS)-induced endotoxemia.13,14 PECAM-1 deficiency
has also been shown to affect NO bioavailability, either as a
consequence of decreased production of NO19 or increased production
of reactive oxygen species.20 Thus, either increased vascular
permeability or decreased NO bioavailability could contribute to the
increased atherosclerosis observed in the aortic sinuses and
descending aortas of mice with PECAM-1–deficient relative to PECAM1–positive endothelium.
The inhibitory effect of PECAM-1 on lesion development in the
aorta as a whole, in contrast, required its expression not only on
endothelial cells but also on hematopoietic cells. The hematopoietic
cells thought to play crucial roles in atherosclerotic lesion development
include monocytes, T lymphocytes, and platelets.1,3 There is ample
evidence that PECAM-1 inhibits platelet responsiveness,30,37 and
PECAM-1 is also capable of interfering with both macrophage-mediated
phagocytosis of viable cells38,39,40 and T cell receptor–mediated
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol 28, No. 11 (July 31, 2008): pg. 1996-2002. DOI. This article is ©
American Heart Association and permission has been granted for this version to appear in e-Publications@Marquette.
American Heart Association does not grant permission for this article to be further copied/distributed or hosted
elsewhere without the express permission from American Heart Association.

16

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

signaling pathways.41 Indeed, loss of PECAM-1 from circulating T cells
correlated with occurrence of atherothrombotic plaque complications in
humans42 and mice.43 Furthermore, in vivo administration of PECAM1/IgG fusion proteins reduced lesion sizes in atherosusceptible mice
coincident with blunted T cell activation, increased numbers of
circulating regulatory T cells, and decreased infiltration of T cells into
accumulating plaque.44 Collectively, these studies support the
conclusion that interactions between PECAM-1–expressing endothelial
cells and either platelets, monocytes, or T cells may decrease
atherosclerosis in aortas of PECAM-1–positive relative to PECAM-1–
negative mice. Studies in which the pecam-1 gene is knocked out in
specific types of hematopoietic cells are needed to determine the
extent to which PECAM-1 expression by any one of these cell types
normally interferes with development of atherosclerosis.
Finally, our findings indicate that PECAM-1 has both
proatherosclerotic and atheroprotective effects on the vasculature;
however, each of these opposing effects dominates in a different
region of the vasculature. Thus, the inner curvature of the arch is
more strongly influenced by the mechanostimulatory and therefore
proatherosclerotic function of PECAM-1, whereas other
atherosusceptible regions of the vasculature are more strongly
influenced by its antiinflammatory and therefore atheroprotective
effects. A possible explanation for the differential sensitivity of these
regions to the mechanosensory versus antiinflammatory roles of
PECAM-1 is that PECAM-1 might influence the type or magnitude of
hemodynamic shear stress to which different regions of the
vasculature are exposed, which can be addressed by comparing the
hemodynamic properties of PECAM-1+/+ versus PECAM-1−/− aortas.45
Alternatively, PECAM-1 might contribute in different ways to the
responses of cells in different regions of the vasculature, even if they
are exposed to the same shear stresses. This possibility is consistent
with the concept that site-specific responses to systemic factors
modulate how atherosclerosis develops in different atherosusceptible
regions.2 In either case, by demonstrating that PECAM-1 both
promotes and impedes development of atherosclerotic lesions in sitespecific ways, our findings provide a more complete understanding of
the factors that interact in complex ways to control initiation and
progression of atherosclerosis.
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